Industry landscapes
The companies, capital and talent shaping life sciences in Canada. Find the leaders. Understand the segments. See where the activity is.
An industry ecosystem,
measured in context.
24 featured companies from the funding, hiring, revenue and team-size leaderboards.
Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗
Recently founded means a recorded 2023–2026 founding year and no recorded parent, acquirer or public-company status. These companies are not labelled startups without that separate classification.
Explore classified startups in Radar ↗A few useful ratios bring the size of this ecosystem into perspective.
148 of 1,979 tracked companies have open roles.
601 of 1,979 tracked companies have a recorded round.
Share of disclosed capital received by the three largest recorded recipients.
Midpoint of 1,286 rounds with a disclosed amount.
Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 68.4% of disclosed capital, while 69.6% of tracked companies have no recorded funding round.
Explore the segments →Recorded company formation and disclosed funding across the complete annual series shown.
Sum of recorded funding rounds · USD
| Year | Funding (USD) | Founded | Raising |
|---|---|---|---|
| 2016 | $567.9M | 115 | 68 |
| 2017 | $944.73M | 109 | 87 |
| 2018 | $8.19B | 117 | 99 |
| 2019 | $1.71B | 107 | 120 |
| 2020 | $1.32B | 129 | 116 |
| 2021 | $1.19B | 72 | 118 |
| 2022 | $742.83M | 50 | 72 |
| 2023 | $820.57M | 49 | 69 |
| 2024 | $1.21B | 19 | 86 |
| 2025 | $819.26M | 7 | 92 |
Share of all disclosed company funding.
1,531 recorded rounds since 2016
Recorded participation in life sciences company rounds since 2016.
Backed by Ontario Canada.
Backed by Ontario Canada.
Backed by Ontario Canada.
Backed by .
Backed by .
Backed by Wittington Ventures and Continuum Health Ventures and others.
Backed by .
Backed by Government of Canada.
Backed by Janus Henderson Investors and Qatar Investment Authority and others.
Backed by SoftBank Vision Fund and CPP Investments and others.
Backed by Versant Ventures and Novartis.
Backed by Shenzhen Capital Group and Panlin Capital and others.
Backed by Novo Holdings and Arkin Holdings and others.
Backed by Fidelity Investments and T. Rowe Price.
Backed by Guoxin Capital and SBCVC and others.
Backed by VenBio and Versant Ventures and others.
Backed by Orbimed and DCVC and others.
Backed by Varian Medical Systems and Perceptive Advisors and others.
The measured Canada identity-to-filing probe did not produce a qualifying designated legal or national-ID join: world_filings_distributed exposes no reviewed Canadian national-ID key; none of the designated Canadian identities carried a CIK.
How the Canada companies on this page show up online: the sites people visit, the apps they install, and how often those apps ship.
6 of the 1,979 companies on this page carry a measured traffic record (0.3%); these are the largest of those, by monthly visits. The median among them is 265,003 visits.
| Company | Monthly visits | Authority | Mobile |
|---|---|---|---|
| DrugBankdrugbank.com | 777,128 | 70 | 31.2% |
| Dynacaredynacare.ca | 410,071 | 49 | 63.2% |
| Immunotecimmunotec.com | 402,397 | 39 | 70% |
| Fresh Prepfreshprep.ca | 127,610 | 39 | 51% |
| Stokostoko.com | 87,052 | 35 | 62.7% |
| Advanced Orthomolecular Researchaor.ca | 32,066 | 39 | 74.2% |
Visits and authority are third-party web estimates, not company-reported figures.
42 of these companies (2.1%) publish at least one Android app — 117 apps in all, carrying 2.3M installs between them.
| App | Installs | Rating | Store category |
|---|---|---|---|
| Clarius UltrasoundClarius | 777.1K | 3.2 | Medical |
| Unitron Remote PlusUnitron | 572K | 4.3 | Medical |
| Just Scale Kitchen ScaleReFleX Wireless | 179.7K | 2.6 | Productivity |
| Hair Removal - Silk\'nSilk\'n | 135.5K | 1.2 | Lifestyle |
| Smart Chef Smart Food ScaleReFleX Wireless | 108.2K | 2.1 | Health & Fitness |
| Fetalbeats 2.0FetalBeats | 93.3K | 2 | Health & Fitness |
| Alcohol SensorReFleX Wireless | 68.1K | — | Health & Fitness |
| ReadiOne by Fatigue ScienceFatigue Science | 40.8K | — | Health & Fitness |
| AvicennaAvicenna Research | 40.7K | 4.2 | Tools |
| Go-KetoGo | 39.8K | — | Health & Fitness |
Installs are lifetime totals to date at the June 2026 store reading — a measure of reach, not of people using an app today.
The busiest app inside each of this page’s own segments, with the quarterly release trend behind it (2023Q4–2026Q2).
| Segment | Apps | Installs | Leading app | Release trend |
|---|---|---|---|---|
| Healthcare It | 17 | 870K | Clarius Ultrasound 777.1K | |
| Wearable Technology | 19 | 659.2K | Unitron Remote Plus 572K | |
| Assistive Tech | 3 | 572.3K | Trexo Chat 193 | |
| Disease Self Management | 34 | 568.1K | Just Scale Kitchen Scale 179.7K | |
| Fitness & Wellness Tech | 24 | 484.2K | Smart Chef Smart Food Scale 108.2K | |
| Sleep Medicine | 23 | 441.1K | Alcohol Sensor 68.1K | |
| Life Sciences Tech | 58 | 105.3K | Avicenna 40.7K | |
| Women Health | 5 | 94K | Fetalbeats 2.0 93.3K |
A company can carry several segment tags, so these rows overlap and should not be added together. Trend lines are zero-based and share one quarter grid, so a flat line is a quiet segment, not a missing one.
New apps published, beside apps whose most recent update landed in that quarter — the second bar is how much of the shelf is still being maintained.
Darker bars are new releases, lighter bars apps updated. 101 of 117 apps carry a release date. The series ends at 2026Q1, the last quarter that closed before the June 2026 reading.
Explore the segments behind the headline numbers.
Rank segments by scale, hiring or disclosed funding.
Companies can sit in several segments. Counts and funding overlap.
The largest measured segment in this report snapshot.
119 companies hiring · $36.64B disclosed funding
Explore in RadarCommon revenue models; a company can use more than one.
Recorded corporate activity linked to companies in this landscape.
Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) announces that it proposes to complete a private placement (the “Offering”) of up to 2,800,000 units of the Corporation (“Units”) at a price of $0.55 per Unit for gross proceeds of up to $1,540,000.
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce a non-brokered private placement (the "Offering") of up to 40,000,000 units (each, a "Unit") in the capital of the Company at a price of $0.025 per Unit for gross proceeds of up to $1,000,000.
ViewsML raised $4.9M seed round for virtual biomarker staining.
The $CAN 2.66 million financing, in conjunction with the previously announced $CAN 1.1 million equity financing completed on March 10th, strengthens our balance sheet and provides the Company with additional capital to execute on its strategic initiatives.
Organon decided to sell its JADA post-partum haemorrhage (PPH) treatment system to Laborie Medical for up to $465 million.
Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is pleased to announce a non-brokered private placement offering of 14,615,384 common shares in the capital of the Company ("Common Shares") at a price of $0.065 per Common Share, for aggregate gross proceeds of approximately $950,000 (the "Private Placement").
VoxCell BioInnovation in Victoria: $110,000
Aurinia Pharmaceuticals has entered into a definitive agreement to acquire Kezar Life Sciences.
Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced the successful completion by affiliates of Madryn Asset Management, LP (“Madryn”) of a short-form merger transaction, pursuant to which 100% ownership of the Company’s common stock is now consolidated under funds managed by Madryn (the “Short-form Merger”).
RENAISSANCE BIOSCIENCE | Secures a $550,000 Genome BC grant for a 24-month project to build a proprietary wild yeast discovery platform in partnership with the University of British Columbia.
Top 10 categories among 1,757 recorded events in the 24-month window.
26 companies with recorded IPO activity
Follow-on Offering · NASDAQ/TSX3 reports
IPO · Nasdaq Global Market2 reports
Follow-on Offering · NASDAQ1 reports
IPO activity · OTCQB1 reports
IPO activity1 reports
Follow-on Offering · TSX Venture Exchange2 reports
IPO1 reports
IPO · NASDAQ3 reports
76 tracked people moves
Appointment Chief Financial Officer
Appointment Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer
Appointment Board of Directors
Resignation Previously Board of Directors
Appointment Chief Executive Officer and Chairman
Appointment Chief Financial Officer
Resignation Previously Executive Chairman
Appointment Chairman
Products, platforms and features in the recorded window
Recreational cannabis brand
Hormone test
Hormone test
Platform
34 recorded customer wins
Customer: aloe finance
Customer: Nutravisor Inc.Biotechnology / Nutraceutical
Customer: Nutrition and ingredients organizationNutrition
Customer: NASDAQ-listed pharmaceutical companyPharmaceutical
Customer: Province of OntarioLife Sciences
Customer: xenotherapeuticsPharmaceutical/Biotechnology
7 companies with reported reductions
105 rolesbusiness downturn
49 rolescost reduction
57.0% rolescost reduction
75.0% rolescost reduction
115 rolescost reduction
64 rolescost reduction
65 recorded events
submitted for approvalChina\'s National Medical Products Administration
license grantedHealth Canada
approved for share consolidationTSX Venture Exchange and Nasdaq Stock Exchange
pending reviewAlberta Securities Commission
15 tracked suits
shareholder claim alleging improper and oppressive actionsCivil · Settled
shareholder claimCivil · Settled
Reported company results in the recorded window.
Median across 182 reported growth observations; companies may contribute multiple periods.
Company-linked deal reports; status is preserved as recorded.
| Acquirer → target | Status | Date | Value / context |
|---|---|---|---|
| Psyence→goldcoast | Announced | 2026-04-13 | Not stated in snapshot |
| Laborie Medical→organon | 2026-04-10 | $465.0M | |
| Laborie Medical→JADA post-partum haemorrhage treatment system | Completed | 2026-04-10 | $465.0M |
| XORTX Pharma→vectus biosystems | Announced | 2026-04-02 | Not stated in snapshot |
| Aurinia Pharmaceuticals→kezar life sciences | Announced | 2026-04-01 | Not stated in snapshot |
| madryn asset management→venus concept ↗ | Completed | 2026-03-30 | Not stated in snapshot |
A discussion or rumour is not a completed transaction. An unstated value is not zero.
1,512 postings in the preceding 12 months. The full 2,834-posting snapshot covers 111 employers.
14 tracked postings mention remote work.
531 postings specify a level.
Top skills across 2,834 tracked postings in the available jobs snapshot.
Median across 240 postings with pay data, expressed in USD.
| Company | Open roles |
|---|---|
| Fresh Prep ↗ | 11 |
| Dynacare ↗ | 11 |
| Amico ↗ | 11 |
| Bausch Health ↗ | 10 |
| Optel Group ↗ | 9 |
| Able Innovations ↗ | 8 |
| Sonic Incytes ↗ | 8 |
| Kinova ↗ | 8 |
| Company | Employees |
|---|---|
| Patterson Dental ↗ | 6,772 |
| Dynacare ↗ | 2,400 |
| Bausch Health ↗ | 808 |
| Abcellera Biologics ↗ | 560 |
| Actlabs ↗ | 452 |
| Fresh Prep ↗ | 431 |
| Benchsci ↗ | 426 |
| Ocean Nutrition Canada ↗ | 415 |
1,210 founders and chief executives across 931 companies.
Ex-Creo Angel Investor.Stanford University Graduate School of Business MBA 1981.
Fudan University BSc, Dalhousie University, UBC PhD
Promis Tm Neurosciences, ex-Immune Pharma, ex-Dart Therapeutics, McGill University (BSc); University of Aix-Marseille, France (MD)
Ex-Microsoft Research · University of Manitoba MSc 1993, University of Toronto PhD 1997
NYU Langone Medical Center. American University of Beirut BS 2001, The University of Texas Southwestern Medical Center PhD 2005
University of Buea 2006, McMaster University MSc 2012, University of Toronto PhD 2019
Ex-Sanofi Pasteur, Roche. University St.Gallen MBA
Abdera Therapeutics, LifeSciences BC, ex-adMare BioInnovations. Harvard University AB 1989, McGill University PhD 1998
Ex-ABK Biomedical, Ellex, President and CEO ReShape Medical. Saint Joseph's University BS, Marketing 1992
Tela Bio, ex-Vesper Medical, ex-Intact Vascular, university of pennsylvania, 1970
Ex-Founder-Caprion Pharmaceuticals, CEO-Clementia Pharmaceuticals, Cepmed, Bioconcept · McGill University PhD 1992
University of Toronto PhD 2008
233 profiles with education records.
5 profiles with prior-work records.
Profiles cover recorded founders and leaders; contact details remain in Radar.
25,872 articles in the measured 12-month window.
Life Sciences coverage across Canada · articles per complete quarter
| Quarter | Articles |
|---|---|
| 2021Q2 | 10,284 |
| 2021Q3 | 8,585 |
| 2021Q4 | 6,717 |
| 2022Q1 | 8,000 |
| 2022Q2 | 7,222 |
| 2022Q3 | 6,402 |
| 2022Q4 | 7,064 |
| 2023Q1 | 6,675 |
| 2023Q2 | 8,245 |
| 2023Q3 | 8,044 |
| 2023Q4 | 6,816 |
| 2024Q1 | 7,355 |
| 2024Q2 | 8,035 |
| 2024Q3 | 7,145 |
| 2024Q4 | 7,900 |
| 2025Q1 | 22,276 |
| 2025Q2 | 5,759 |
| 2025Q3 | 6,102 |
| 2025Q4 | 6,085 |
| 2026Q1 | 7,937 |
Article volume measures coverage, not market sales.
2,465 recorded company events across 225 companies; percentages use that event total.
Life Sciences coverage across Canada · ranked by full-period article count.
Recent and prior counts use the source comparison windows.
Life Sciences coverage across Canada
| Keyword | Recent | Prior | Change |
|---|---|---|---|
| angel investors | 1,014 | 361 | 181% |
| asset acquisition | 407 | 140 | 191% |
| early-stage investment | 404 | 130 | 211% |
| vaccine candidates | 320 | 70 | 357% |
| vaccine trials | 318 | 67 | 375% |
| vaccination campaigns | 258 | 40 | 545% |
| vaccine immunogenicity | 250 | 53 | 372% |
| mass vaccination sites | 160 | 18 | 789% |
| vaccination coverage | 128 | 26 | 392% |
| vaccine effectiveness study | 124 | 27 | 359% |
| biosimilar approval | 124 | 245 | -49% |
| copa libertadores | 0 | 243 | -100% |
| biosimilar market entry | 128 | 204 | -37% |
| gene therapy rare diseases | 87 | 197 | -56% |
| biosimilar efficacy | 99 | 178 | -44% |
Life Sciences coverage across Canada
vaccine candidates, vaccine trials, vaccine immunogenicity
39.2% critical · 42.7% positiveangel investors, asset acquisition, early-stage investment
40.1% critical · 56.3% positiveearnings report, quarterly results, biosimilar market entry
31.6% critical · 46.5% positiveLife Sciences coverage across Canada. Topic labels describe recorded classifications and can include broad context.
53,147 papers in the recorded worldwide scope.
Tone counts: 42,568 positive · 8,415 neutral · 2,164 negative.
Landmark: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term prob
Landmark: Genomic responses in mouse models poorly mimic human inflammatory diseases
Landmark: Copper-Zinc Superoxide Dismutase (SOD1) Is Released by Microglial Cells and Confers Neuroprotection against 6-OHDA Neurotoxicity
Common problems researchers identify · 0117.3% of this theme group
Challenges in using microbes and plants for renewable fuels and biorefinery processes.
Biofuel (41) · Synthetic biology (53) · Biomass (45) · Biorefinery (28)
A review on the plant microbiome: Ecology, functions, and emerging trends in microbial application
Biofertilizers: An ecofriendly technology for nutrient recycling and environmental sustainability
| Year | Share index |
|---|---|
| 2022 | 60.4 |
| 2023 | 59.2 |
| 2024 | 62.0 |
| 2025 | 66.9 |
Common problems researchers identify · 0216.8% of this theme group
Issues surrounding microbial hazards, nutritional quality, and health impacts of processed foods.
Food safety (130) · Food processing (74) · Food products (50) · Human health (90)
Microbial Risks in Food: Evaluation of Implementation of Food Safety Measures
Nutritional quality and processing of plant proteins for healthy and sustainable foods
| Year | Share index |
|---|---|
| 2022 | 69.7 |
| 2023 | 71.2 |
| 2024 | 76.2 |
| 2025 | 98.4 |
Common problems researchers identify · 0315.8% of this theme group
Barriers in controlling gene activity, mRNA delivery, and cell‑culture models for disease research.
Messenger RNA (28) · Gene (44) · Cell culture (23) · Gene expression (24)
Analysis of Cancer Metabolism by Imaging Hyperpolarized Nuclei: Prospects for Translation to Clinical Research
Evolution of Approaches to the Development, Life Cycle Control, and Interchangeability of Veterinary Biosimilars Based on Hemoproteins (with
| Year | Share index |
|---|---|
| 2022 | 2508.3 |
| 2023 | 2505.5 |
| 2024 | 2206.6 |
| 2025 | 1725.8 |
Common problems researchers identify · 0415.4% of this theme group
Limitations in fertilizer use, nutrient uptake, and breeding strategies for resilient agriculture.
Agriculture (208) · Crop (84) · Food security (86) · Germplasm (39)
Revisiting fertilisers and fertilisation strategies for improved nutrient uptake by plants
Breeding for nutrient use efficiency in crop plants: Mechanistic insights, genetic determinants, and emerging breeding technologies
| Year | Share index |
|---|---|
| 2022 | 1631.9 |
| 2023 | 1660.6 |
| 2024 | 1795.2 |
| 2025 | 2000.4 |
Common problems researchers identify · 0515.3% of this theme group
Complexities of fungicide resistance, host‑pathogen interactions, and integrated pest control.
Fungicide (44) · Integrated pest management (54) · Host (41) · Disease management (32)
Innate Immunity in Plants: An Arms Race Between Pattern Recognition Receptors in Plants and Effectors in Microbial Pathogens
Insect-Borne Plant Pathogens and Their Vectors: Ecology, Evolution, and Complex Interactions
| Year | Share index |
|---|---|
| 2022 | 27.7 |
| 2023 | 29.4 |
| 2024 | 27.9 |
| 2025 | 37.4 |
Common problems researchers identify · 069.9% of this theme group
Widespread emergence of drug‑resistant microbes in humans, livestock, and the environment.
Antibiotic resistance (301) · Antimicrobial (164) · Antibiotics (126) · Drug resistance (49)
Antimicrobial resistance in humans, livestock and the wider environment
Antimicrobial use and resistance
| Year | Share index |
|---|---|
| 2022 | 882.3 |
| 2023 | 835.4 |
| 2024 | 912.9 |
| 2025 | 968.7 |
Common problems researchers identify · 079.4% of this theme group
Diverse, unrelated research areas lacking a clear thematic focus.
Order (19) · NAD+ kinase (11) · Human being (12) · Sodium (11)
Modalidade, polaridade e legibilidade em resumos académicos: uma análise comparativa multidisciplinar
Obiteljska grupna konferencija: prilika za građansko pravosuđe?
| Year | Share index |
|---|---|
| 2022 | 18.2 |
| 2023 | 21.4 |
| 2024 | 17.1 |
| 2025 | 12.4 |
Cautions · 0121.5% of this theme group
Need for careful interpretation of in‑vitro and in‑vivo assays measuring stress responses.
In vivo (32) · Flow cytometry (16) · In vitro (27) · Oxidative stress (19)
Effects of Microplastics on Cell Viability, Phagocytic Activity and Oxidative Stress in Human Peripheral Blood Mononuclear Cells
Cell Painting for cytotoxicity and mode-of-action analysis in primary human hepatocytes
| Year | Share index |
|---|---|
| 2022 | 1032.2 |
| 2023 | 1112.2 |
| 2024 | 911.3 |
| 2025 | 828.7 |
Cautions · 0214.6% of this theme group
Caution about translating genomic predictions into practical crop improvement.
Agriculture (45) · Selection (26) · Production (28) · Trait (16)
Genomic selection in plant breeding: from theory to practice
Future Directions for Sustainable Poultry Feeding and Product Quality: Alternatives from Insects, Algae and Agro-Industrial Fermented By-Pro
| Year | Share index |
|---|---|
| 2022 | 1433.4 |
| 2023 | 1471.3 |
| 2024 | 1631.9 |
| 2025 | 1793.7 |
Cautions · 0313.9% of this theme group
Potential unintended effects of novel feed compounds on animal health and sustainability.
Feed additive (27) · Animal feed (28) · Feed conversion ratio (32) · Health benefits (30)
Natural Bioactive Compounds as Feed Additives: Strategies for Sustainable and Functional Livestock Production
The impact of substituting animal with plant protein foods in adults’ self-selected diets on environmental, nutritional, and health outcomes
| Year | Share index |
|---|---|
| 2022 | 21.2 |
| 2023 | 19.9 |
| 2024 | 17.3 |
| 2025 | 17.6 |
Cautions · 0413.6% of this theme group
Risks associated with emerging food additives, contaminants, and their regulatory assessment.
Food safety (66) · Hygiene (21) · Contamination (29) · Food contaminant (20)
Caffeine (1, 3, 7‐trimethylxanthine) in Foods: A Comprehensive Review on Consumption, Functionality, Safety, and Regulatory Matters
Insect-derived food colorants: Chemistry, applications, safety, and regulatory perspectives
| Year | Share index |
|---|---|
| 2022 | 92.1 |
| 2023 | 89.1 |
| 2024 | 94.2 |
| 2025 | 105.4 |
Cautions · 0513.5% of this theme group
Uncertainties in interpreting gene‑expression changes linked to genomic instability.
Gene (41) · DNA damage (26) · DNA repair (13) · Gene expression (20)
Comparative analysis of microRNA expression in serum and plasma in patients screened for BRCA1 or BRCA2 mutations
Homologous recombination deficiency in primary ER-positive and HER2-negative breast cancer
| Year | Share index |
|---|---|
| 2022 | 2414.1 |
| 2023 | 2426.1 |
| 2024 | 2133.7 |
| 2025 | 1642.1 |
Cautions · 0611.7% of this theme group
Complex dynamics of resistance development when antibiotics mix with biocides or metals.
Antibiotic resistance (59) · Antibiotics (47) · Antimicrobial (38) · Bacteria (26)
Antibiotic use in food animals worldwide, with a focus on Africa: Pluses and minuses
Co-Selection of Resistance to Antibiotics, Biocides and Heavy Metals, and Its Relevance to Foodborne Pathogens
| Year | Share index |
|---|---|
| 2022 | 882.3 |
| 2023 | 835.4 |
| 2024 | 912.9 |
| 2025 | 968.7 |
Cautions · 0711.3% of this theme group
Challenges in designing dosing strategies that avoid resistance while maintaining efficacy.
Pesticide (34) · Integrated pest management (21) · PEST analysis (30) · Biological pest control (20)
The use of fungal entomopathogens as endophytes in biological control: a review
Managing pesticide resistance by changing the applied dose: a modeling analysis incorporating pesticide persistence and including low-dose m
| Year | Share index |
|---|---|
| 2022 | 66.0 |
| 2023 | 65.3 |
| 2024 | 66.9 |
| 2025 | 76.7 |
Opportunities · 0117.4% of this theme group
Emerging platforms for in‑vivo labeling, fluorescence, and flow‑cytometry applications.
Antibody (70) · In vivo (81) · Fluorescence (40) · Flow cytometry (50)
Figure 4 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcom
Preparation, Characterization, and Binding Mechanism of Nanobodies Targeting Multiple Serotypes of <i>Salmonella</i>
| Year | Share index |
|---|---|
| 2022 | 560.8 |
| 2023 | 617.6 |
| 2024 | 466.3 |
| 2025 | 459.8 |
Opportunities · 0217.2% of this theme group
Promising approaches using knockdown, apoptosis control, and cell‑growth modulation.
Downregulation and upregulation (106) · Apoptosis (80) · Gene knockdown (103) · Cell growth (43)
Fat Mass and Obesity‐Associated Protein Contributes to Tumorigenesis and Drug Resistance of Diffuse Large B‐Cell Lymphoma by Suppressing <sc
RasGRP3 Promotes RAP1B Activity to Inhibit Endothelial Inflammation and Alleviate Atherosclerosis in High-Fat Diet-Fed ApoE−/− Mice
| Year | Share index |
|---|---|
| 2022 | 362.8 |
| 2023 | 394.7 |
| 2024 | 255.9 |
| 2025 | 266.9 |
Opportunities · 0314.6% of this theme group
Development of antioxidant‑rich ingredients and health‑promoting food products.
Health benefits (78) · Functional food (61) · Ingredient (48) · Antioxidant (69)
Plant-based functional foods for healthy aging: current trends, bioactive compounds, and future perspectives
PLANT-BASED PROTEINS: SOURCES, EXTRACTION METHODS AND FUNCTIONAL PERSPECTIVES FOR THE SUSTAINABLE FOOD INDUSTRY
| Year | Share index |
|---|---|
| 2022 | 26.7 |
| 2023 | 25.8 |
| 2024 | 27.4 |
| 2025 | 44.8 |
Opportunities · 0413.7% of this theme group
Innovations in DNA methylation profiling and miRNA detection for disease monitoring.
Gene (164) · DNA methylation (60) · Messenger RNA (76) · DNA damage (55)
Convergent DNA methylation abnormalities at enhancers and bivalent promoters in human growth disorders
Stimuli-ResponsiveFusion of Binary-Star IntelligentDNA System for the Signal-On Amplification Detection of Cancer-RelatedmiRNA
| Year | Share index |
|---|---|
| 2022 | 2396.5 |
| 2023 | 2385.8 |
| 2024 | 2123.6 |
| 2025 | 1641.4 |
Opportunities · 0513.5% of this theme group
Exploration of plant‑derived compounds and postbiotic products to combat resistance.
Antimicrobial (126) · Antibiotic resistance (66) · Biological pest control (54) · Bacteria (87)
Plants as sources of new antimicrobials and resistance-modifying agents
Postbiotics: Multifunctional Microbial Products Transforming Animal Health and Performance
| Year | Share index |
|---|---|
| 2022 | 524.8 |
| 2023 | 510.2 |
| 2024 | 556.9 |
| 2025 | 654.9 |
Opportunities · 0611.9% of this theme group
Leveraging quantitative trait loci and selection to boost crop yields and traits.
Germplasm (71) · Trait (52) · Quantitative trait locus (40) · Selection (53)
Evaluation of Genetic Variability and Trait Interrelationships Using Advanced Wheat Lines to Increase Yield
GENETIC VARIABILITY ANALYSIS FOR YIELD AND RELATED TRAITS IN WHEAT (TRITICUM AESTIVUM L.) MUTANT GENOTYPES
| Year | Share index |
|---|---|
| 2022 | 52.7 |
| 2023 | 45.3 |
| 2024 | 39.3 |
| 2025 | 41.1 |
Opportunities · 0711.6% of this theme group
Utilizing microbial fermentation and agri‑food by‑products for greener energy and materials.
Biomass (67) · Sustainability (77) · Agriculture (102) · Biofuel (35)
Microbial Fermentation: A Sustainable Strategy for Producing High-Value Bioactive Compounds for Agriculture, Animal Feed, and Human Health
Bioactive Compounds From Agri‐Food By‐Products: Advancements in Environmental Sustainability and Bioeconomic Progress
| Year | Share index |
|---|---|
| 2022 | 1511.1 |
| 2023 | 1558.6 |
| 2024 | 1735.8 |
| 2025 | 1952.4 |
Orientation shares compared with 25,000 papers in the reference sample.
| Research orientation | This field | Reference sample |
|---|---|---|
| Descriptive | 40.2% | 17.6% |
| Promising | 30.4% | 37.2% |
| Breakthrough | 14.1% | 26.0% |
| Problem-identifying | 8.3% | 9.8% |
| Cautionary | 3.5% | 4.5% |
| Comparative | 2.4% | 3.8% |
| Critical | 1.0% | 1.0% |
Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.
| Concern / example paper | Papers | Share | Raised as a problem | Worldwide share |
|---|---|---|---|---|
| Privacy & surveillanceSARS-CoV-2 wastewater genomic surveillance: approaches, challenges, and opportunities | 87 | 0.21% | 25 (28.7%) | 0.21% |
| Hardware, e-waste & supply chainFate and Transport of Antibiotic Residues and Antibiotic Resistance Genes following Land Application of Manure Waste | 61 | 0.15% | 4 (6.6%) | 0.15% |
| Bias & fairnessGeographic Prevalence Heterogeneity Creates Unavoidable Fairness-Accuracy Trade-offs in Antimicrobial Resistance Predict | 12 | 0.03% | 2 (16.7%) | 0.03% |
| Safety & misusePublic perceptions and information sources on genetically modified organisms in Kenya | 3 | 0.01% | 3 (100.0%) | 0.01% |
| Energy & datacenter footprintIntegration of GWAS and WGCNA Identifies PUE‐Related Gene <i>TaERF112</i> in Wheat | 1 | 0.0% | 0 (0.0%) | 0.0% |
| Water use | 0 | 0.0% | 0 (%) | 0.0% |
| Carbon & emissions of compute | 0 | 0.0% | 0 (%) | 0.0% |
| Labour & data work | 0 | 0.0% | 0 (%) | 0.0% |
| Concentration of compute power | 0 | 0.0% | 0 (%) | 0.0% |
Research orientation and citation rankings describe the covered collection. Its recorded publication dates do not support an overall publication-volume trend.
Institution and researcher rankings use citations to their covered work. Research scope: worldwide. This may be broader than the company geography.
Compare demand signals in Canada’s newsflow with the life sciences categories mapped to each signal.
Signal percentile − supply percentile = gap in percentile points. Positive gaps highlight questions to investigate. A high signal can reflect spending pressure or access friction, as well as potential demand.
The comparison is relative to the signal families on this page. A supply percentile of zero means the lowest relative reading, not zero companies. It is a prioritisation clue, not measured market size or unmet demand.
Signal and mapped-supply percentiles, their gap, and change in the signal’s article share.
Swipe horizontally to compare all columns →
| Signal family | Signal percentile | Supply percentile | Relative gap | Gap (points) | Signal share vs prior year |
|---|---|---|---|---|---|
| Infectious outbreaks ↗Disease Burden | 66.7 | 20.0 | +46.7 | +95.2% | |
| Maternal & child health ↗Disease Burden | 83.3 | 40.0 | +43.3 | +74.4% | |
| Ageing & elder care ↗Disease Burden | 8.3 | 0.0 | +8.3 | +5.4% | |
| Layoffs & income shocks ↗Spending Pressure | 66.7 | 80.0 | -13.3 | +20.9% | |
| Air pollution ↗Environmental Driver | 41.7 | 60.0 | -18.3 | +60.3% | |
| Cancer burden ↗Disease Burden | 25.0 | 100.0 | -75.0 | -23.5% | |
| Mental health ↗Disease Burden | 58.3 | — | No matching category | — | +37.2% |
Showing all 7 signals. Select a family for its history and mapped categories.
All 9 city readings for these demand families in the comparison geography. Canada is highlighted.
Each city’s reading is a share of its own coverage.
Maternal & child health · Mental health · Infectious outbreaks
Maternal & child health · Mental health · Layoffs & income shocks
Mental health · Maternal & child health · Cancer burden
Layoffs & income shocks · Cancer burden · Mental health
Ageing & elder care · Maternal & child health · Infectious outbreaks
Maternal & child health · Mental health · Air pollution
Mental health · Infectious outbreaks · Maternal & child health
Maternal & child health · Layoffs & income shocks · Mental health
Layoffs & income shocks · Mental health · Air pollution
Outbreak pressure can pull testing, surveillance and rapid-care demand at short notice.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 21 | 2.99 |
| 2024Q4 | 29 | 3.86 |
| 2025Q1 | 29 | 2.97 |
| 2025Q2 | 21 | 3.22 |
| 2025Q3 | 67 | 5.22 |
| 2025Q4 | 45 | 10.89 |
| 2026Q1 | 30 | 6.24 |
Maternal and child burden can pull immunisation, nutrition and pediatric care demand.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 79 | 11.24 |
| 2024Q4 | 84 | 11.19 |
| 2025Q1 | 75 | 7.68 |
| 2025Q2 | 65 | 9.97 |
| 2025Q3 | 223 | 17.37 |
| 2025Q4 | 49 | 11.86 |
| 2026Q1 | 68 | 14.15 |
An ageing base can shift demand toward geriatric, home and chronic care.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 39 | 5.55 |
| 2024Q4 | 50 | 6.66 |
| 2025Q1 | 33 | 3.38 |
| 2025Q2 | 34 | 5.21 |
| 2025Q3 | 44 | 3.43 |
| 2025Q4 | 24 | 5.81 |
| 2026Q1 | 44 | 9.15 |
Layoff cycles can pull discretionary spend back toward value offerings.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 116 | 16.51 |
| 2024Q4 | 107 | 14.25 |
| 2025Q1 | 135 | 13.83 |
| 2025Q2 | 93 | 14.26 |
| 2025Q3 | 160 | 12.46 |
| 2025Q4 | 93 | 22.51 |
| 2026Q1 | 111 | 23.09 |
Sustained air-quality stress can pull respiratory and cardiac care demand with it.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 43 | 6.12 |
| 2024Q4 | 19 | 2.53 |
| 2025Q1 | 44 | 4.51 |
| 2025Q2 | 26 | 3.99 |
| 2025Q3 | 115 | 8.96 |
| 2025Q4 | 30 | 7.26 |
| 2026Q1 | 14 | 2.91 |
Cancer burden can pull screening, diagnostics and oncology capacity demand.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 77 | 10.96 |
| 2024Q4 | 84 | 11.19 |
| 2025Q1 | 85 | 8.71 |
| 2025Q2 | 41 | 6.29 |
| 2025Q3 | 78 | 6.08 |
| 2025Q4 | 38 | 9.2 |
| 2026Q1 | 31 | 6.45 |
Mental-health pressure can pull counselling and tele-psychiatry demand where it surfaces.
This signal has no matching category in the page’s life sciences market map, so no supply percentile or gap is assigned.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 62 | 8.82 |
| 2024Q4 | 51 | 6.79 |
| 2025Q1 | 40 | 4.1 |
| 2025Q2 | 88 | 13.49 |
| 2025Q3 | 89 | 6.93 |
| 2025Q4 | 54 | 13.07 |
| 2026Q1 | 68 | 14.15 |
Canada life sciences coverage
Bipolar Disorders
1,710 citations in the snapshot
Health Research Policy and Systems
500 citations in the snapshot
European Heart Journal
421 citations in the snapshot
Eurosurveillance
410 citations in the snapshot
Canada coverage of this page's demand families
| Keyword | Recent articles | Prior articles | Share change |
|---|---|---|---|
| provider vaccine recommendations | 65 | 21 | 258.7% |
| cdc vaccination calendar | 75 | 29 | 199.7% |
| catch-up immunization schedule | 57 | 24 | 175.2% |
| air quality standards | 45 | 51 | 2.2% |
| support groups cancer | 40 | 62 | -25.2% |
Share changes describe coverage in the stated comparison periods, not search demand or market size.
Company counts, hiring and disclosed funding across the recorded hubs.
36.0% across the displayed hubs
29 companies hiring · $3.2B disclosed funding
Explore companies in Toronto ↗
21.3% across the displayed hubs
18 companies hiring · $2.5B disclosed funding
Explore companies in Vancouver ↗
17.0% across the displayed hubs
19 companies hiring · $1.9B disclosed funding
Explore companies in Montreal ↗
6.8% across the displayed hubs
4 companies hiring · $632.3M disclosed funding
Explore companies in Calgary ↗
4.9% across the displayed hubs
3 companies hiring · $567.5M disclosed funding
Explore companies in Mississauga ↗
4.8% across the displayed hubs
6 companies hiring · $301.0M disclosed funding
Explore companies in Edmonton ↗
4.7% across the displayed hubs
3 companies hiring · $158.5M disclosed funding
Explore companies in Ottawa ↗4.4% across the displayed hubs
3 companies hiring · $434.1M disclosed funding
Explore companies in Quebec City ↗Clear definitions for making better comparisons.
It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.
No. A company can belong to several segments, so segment counts and funding can overlap.
A dash or unavailable panel means the current reviewed source snapshot does not support that figure.
Company ecosystem snapshot: 6 August 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.
Canonical landscape ↗